An observational study in NAFLD, Cardiac Disease and Fatty Liver, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Non-alcoholic Fatty Liver Disease with a site in India — 10 open to participants now, 13 under way, 6 of them phase 3. Non-alcoholic Fatty Liver Disease · India.
Among the 44 studies in Non-alcoholic Fatty Liver Disease with a site in India, this one is one of 10 that started in 2023, is one of 5 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 34th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →10 of the 44 studies in Non-alcoholic Fatty Liver Disease with a site in India are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in India, United States, Argentina and 31 more countries
Ages 18+
Akero Therapeutics, Inc · Sites in India, United States, Argentina and 20 more countries
Ages 18–80
The Cleveland Clinic · Sites in India, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–65
Hoffmann-La Roche · Sites in India, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 152 across 391 observational studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 144 across the 39 interventional studies, 150 across the 5 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 44 have an industry lead sponsor. The 10 most frequent:
Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 298 studies on the registry; 43 are open to participants now.
Post Graduate Institute of Medical Education and Research, Chandigarh has 2 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Non-alcoholic Fatty Liver Disease with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06015620All India Institute of Medical Sciences, BhubaneswarComorbidities Resolution After MGB Surgery and Change in Body Composition | 2026-12-31 |
| NCT06386094Post Graduate Institute of Medical Education and Research, ChandigarhCardiac Dysfunction in Patients with Fatty Liver Disease | 2027-08-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Non-alcoholic Fatty Liver Disease with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.
Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are obesity-related conditions with high cardiovascular mortality. Many new studies have linked NAFLD to changes in myocardial energy metabolism, and to echocardiographic measurements of cardiac dysfunction especially heart failure with preserved ejection fraction. Cardiac dysfunction in NAFLD is related to the release of inflammatory cytokines among those with steatohepatitis (NASH). However composite models looking at coronary artery disease, systolic and diastolic heart failure and outcomes in patients with NAFLD are limited, and the few preliminary analyses of this relationship using histologically-defined NASH or lean NAFLD remain unclear.
In this project the investigators will screen patients with a diagnosis of 'non-alcoholic fatty liver disease' for presence of coronary artery disease, arrhythmias, cirrhotic cardiomyopathy and develop a model for cardiac dysfunction in such patients.
The target population for this study is all patients with a diagnosis of metabolic dysfunction associated steatotic liver disease seen in the outpatient and inpatient services of the Department of Hepatology, PGIMER Chandigarh.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non invasive tests like APRI, FIB-4, , FAST scan and VCTE in the form of Fibroscan will be done and recorded. Liver biopsy would be done as per the clinical indication. Diagnosis of NAFLD will be based on history, physical examination, laboratory investigations, upper gastrointestinal endoscopy, imaging studies (ultrasonography and Doppler of spleno portal venous axis, VCTE) and liver biopsy where available.
Diagnostic Test: Echocardiographic assessment
M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
To determine the prevalence of cardiac dysfunction in patients with non-alcoholic fatty liver disease/ metabolic dysfunction associated steatotic liver disease
Prevalence of CCM in the MASLD cohort
Time frame: At Enrolment
Presence of myocardial abnormalities in CCM dysfunction
Use of cardiac MRI or CT
Time frame: At Enrolment
Presence of perfusion abnormalities in CCM dysfunction
Use of LV scintigraphy
Time frame: At Enrolment
All cause mortality in metabolic dysfunction associated steatotic liver disease
All cause mortality will be recorded
Time frame: 12 months after enrolment
Cardiac event related mortality in MASLD
Cardiovascular events like incidence of arrhythmia, symptomatic heart failure related deaths will be recorded.
Time frame: 12 months after enrolment
To determine the severity of cardiac dysfunction in patients with metabolic dysfunction associated steatotic liver disease
Prevalence of CCM in the MASLD cohort, and grade of LV diastolic and systolic dysfunction
Time frame: At Enrolment
Plan to share: Undecided
Started Jul 2023 (actual). Primary completion is estimated for Aug 2027, 49 months after the start.
Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's planned 49 months is below that.
Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
Post Graduate Institute of Medical Education and Research, Chandigarh →